Blueprint Medicines Announces Top-line Results from Phase 3 VOYAGER Trial of Avapritinib versus Regorafenib in Patients with Advanced Gastrointestinal Stromal Tumor

VOYAGER did not meet the primary endpoint of an improvement in progression-free survival for avapritinib versus regorafenib in patients with third- or fourth-line GIST Plan to continue to prioritize portfolio opportunities in systemic mastocytosis and R... Biopharmaceuticals, Oncology Blueprint Medicines, avapritinib, gastrointestinal stromal tumor
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news